Gentamicin is an aminoglycoside antibiotic. It exhibits bactericidal activity against aerobic gram-negative bacteria makes gentamicin a good option to treat several common infections. Since gentamicin has a minimal gastrointestinal absorption, its administration is usually by parenteral routes, including systemic, topical and ophthalmic formulations. Although there are reports of resistant strains of gram-negative bacteria, most of these microbes, which have aerobic or facultative metabolism, are susceptible to the gentamicin and other aminoglycosides. The most common microorganisms in clinic settings that present appropriate therapeutic response are members of the Enterobacteriaceae family (e.g., Escherichia coli, Klebsiella pneumoniae, Serratia spp. and Enterobacter spp.), Pseudomonas aeruginosa, and some strains of Neisseria, Moraxella, and Haemophilus genera. A significant percentage of coagulase-negative staphylococci and methicillin-susceptible Staphylococcus aureus isolates show inhibition by gentamicin in clinical drug concentration, although they can readily develop resistance.
According to the Food and Drug Administration (FDA) orientations, gentamicin should be used conformed with culture and susceptibility information, whenever they are possible. However, the option for gentamicin is also appropriate when based on epidemiological data. Therefore, it has applications in several clinical scenarios, such as bacterial septicemia, meningitis, urinary tract infections, gastrointestinal tract (including peritonitis) and soft tissue infection, but always using additional information (e.g., patient age, symptoms, and signs at presentation, local antimicrobial resistance patterns) to enhance the probability to use gentamicin against susceptible germs. The combination with another antibiotic, especially beta-lactams, is reasonable in bacterial endocarditis, enterococcal bacteremia, and other severe infections, although other antibiotics are preferable in these settings. The beta-lactams break the bacterial cell wall and allow gentamicin to get in the bacterial cytoplasm where it can access the ribosomal target, explaining why this combination can be useful against gram-positive bacterial infection.
Gentamicin, an aminoglycoside antibiotic, is bactericidal. Gentamicin passes through the gram-negative membrane in an Oxygen-dependent active transport. As oxygen is required, this is why aminoglycosides are not effective in anaerobic bacteria.
Once in the cytoplasm, gentamicin and other aminoglycosides bind to the 16s rRNA at the 30s ribosomal subunit, disturbing the translation of mRNA and, thus, leading to the formation of truncated or nonfunctional proteins. The mechanism of the bactericidal activity of gentamicin has not been fully elucidated yet, but some propose that truncated proteins are placed at the cell wall, compromising its impermeability, while others also suggest that accumulation of reactive oxygen species, as a consequence of depletion of proteins involved with oxidation-reduction reactions, may lead to bacterial death.
Gentamicin, like all aminoglycosides, exhibit concentration-dependent killing. Higher concentrations correlate with greater antimicrobial killing. For these reasons, peaks and troughs should be monitored closely with systemic use. Additionally, research has noted the synergistic effects of aminoglycosides on gram-positive bacteria when combined with other medications have been mentioned, but the mechanism is unknown.
Gentamicin is generally available in parenteral, ophthalmic, and topical preparations. The parenteral route encompasses, mainly, intramuscular and intravenous administration, whose doses of both are calculated based on the patient weight. For moderate and morbidly obese patients, the weight for dose calculation equals 0.4 multiplied by excess body weight plus estimated ideal body weight. The dose of 5 to 7mg/kg daily given intravenously (infused over 30 to 120 minutes) is the preferable way for gentamicin application in most systemic infections by sensible germs, even though the traditional dosing of 3 to 5 mg/kg/day divided into doses every 8 hours is still an option in certain scenarios. For some non-serious infections, such as pelvic inflammatory disease without sepsis, the daily dose may be administered intramuscularly. Infectious endocarditis caused by staphylococci or enterococci was previously treated with gentamicin along with beta-lactams, although this therapy has been abandoned since the increase in bacterial resistance rates. Gentamicin, usually combined with an anaerobicidal antibiotic, can be applied at a single dose of 5ml/kg 60 minutes before surgical incision in gastrointestinal, urologic, and gynecologic procedures for surgical infection prophylaxis.
When administered as an intramuscular injection, gentamicin achieves peak serum concentrations after 30 to 90 minutes. Because of its polar nature, the penetration into the central nervous system and general cells is minimal, as well as the binding to plasma albumin. The majority of gentamicin is excreted unmetabolized by glomerular filtration, which enables a urinary concentration almost 100-fold higher than of the serum.
The ophthalmic gentamicin preparations exist as ointment and solution, both at 0.3% concentration. They are typically used for bacterial eye infections, such as keratitis and conjunctivitis. The topic gentamicin ointment and cream have a concentration of 0.1% and are restricted specific skin and subcutaneous tissue infections, which usually are secondary to abrasions, cuts, and burns.
Gentamicin and aminoglycosides have some specificities about their antibacterial activity. The bactericidal capacity of aminoglycosides correlates with their peak concentration in such a way that the greater the concentration, enhances bacterial killing. The postantibiotic effect (PAE), another feature of aminoglycosides, is the characteristic for bacterial regrowth suppression that persists a few hours after antibiotic concentration falls below the minimum inhibitory concentration (MIC); high peak concentration also advantages the PAE. Therefore, these properties explain the reason for gentamicin is preferable in high-dose regimens associated with extended-interval doses.
Characteristically, gentamicin reaches high concentrations in the renal cortex and the inner ear. The latter may be injured, leading to auditory and, especially, vestibular dysfunction. The first manifestation of cochlear damage is often high-pitched tinnitus, which may last a few weeks after the gentamicin is interrupted. A high-frequency hearing loss may be present in almost two-thirds of the patients receiving aminoglycosides, including gentamicin, but only a small number complains of hearing impaired. The vestibular toxicity manifests as nausea, vomiting, balance disorder, and vertigo within the two first weeks. A chronic phase, which may persist for about two months, is marked for ataxia and not rarely leaves some residual dysfunctions. The gentamicin is prone to accumulate in the renal proximal tubular cells and can cause damage. Hence, mild proteinuria and reduction of the glomerular filtration rate are potential consequences of gentamicin use, achieving 14% of gentamicin users in a review. Once proximal tubular cells carry regeneration capacity, renal injury and its consequences often are reversible. When compared with the high-dose, extended interval dosing approach, the divided-doses scheme implies a longer time of gentamicin serum concentration above the toxicity threshold, resulting in a higher risk for ototoxicity and nephrotoxicity.
The neuromuscular blockade, although a rare event, is a serious adverse effect of virtually all aminoglycosides. The known risk factors are concurrent conditions (e.g., myasthenia gravis) or medications (e.g., vecuronium) that interfere with the neuromuscular junction. The blockade probably results from a reduction of presynaptic release of acetylcholine and interference of acetylcholine postsynaptic receptors function, both effects mediated by aminoglycosides. The intravenous administration of calcium can overcome this toxicity.
The absolute contraindication for gentamicin use is a history of hypersensitivity reaction to it or other aminoglycosides, although this is a rare event. In cases of renal impairment, dosing adjustment should be made based on the glomerular filtration rate (GFR); for high-dose, extended interval dosing approach, the dose can be preserved, but the interval between doses should increase in line with GFR decrease. In burn patients, the systemic absorption of topical gentamicin may be enhanced, and one should be watchful for the potential repercussions. Systemic gentamicin belongs to category D of FDA pregnancy risk classification (i.e., although the evidence of human fetal risk, its use is acceptable if the possible benefits overcome the risks).
For a brief treatment duration (less than six days) in non-critical patients with suitable renal function, serum gentamicin concentration monitoring often is unnecessary. On the other hand, in case of long periods of treatment or high risk for aminoglycoside toxicity (e.g., older age, concomitant use of other nephrotoxins, preexisting renal disease), dosing monitoring is well indicated. In traditional dosing, the concentration measurement should occur after the patient has received at least three maintenance doses; trough concentration is measured within 30 minutes before the next dose, and peak concentration after 30 minutes of the end of intravenous infusion (in case of intramuscular injection, 60 minutes after the application). For extended-interval dosing, a single serum concentration obtained between 6 to 14 hours after the first administration is sufficient for the assessment and readjustment of subsequent doses, through a nomogram-based evaluation.
Renal function should be evaluated twice-weekly in patients without previous renal disease through serum creatinine and blood urea nitrogen. Periodic microscopic urinalysis is also vital to detect proteinuria and casts, which may indicate kidney injury. Hearing tests must be a consideration in patients with high risk for toxicity or those receiving prolonged therapy. Patients with preexisting neuromuscular disorders or undergoing anesthetic procedures should have monitoring due to the risk of neuromuscular blockade.
The main toxicity that occurs from gentamicin systemic use is nephrotoxicity.
Although a rare event, hypersensitivity reactions secondary to gentamicin administration can be severe, to the extent that cases requesting intensive care unit admissions exist in the literature. There is no antidote for gentamicin toxicity, and the approach for gentamicin-induced hypersensitivity reaction is drug suspension combined with supportive treatment. The possible hypersensitivity manifestations are urticaria, eosinophilia, delayed-type hypersensitivity reaction (Stevens-Johnson syndrome and toxic epidermal necrolysis), angioedema, and anaphylactic shock. The clinical manifestations should guide the treatment strategy. In case of hypotension or even anaphylactic shock, intravenous fluids and vasoactive agents are the primary therapeutic options. Oxygen supplementation or mechanical ventilation may be necessary whether respiratory distress occurs. When Stevens-Johnson syndrome or toxic epidermal necrolysis develops, the mainstay of treatment includes wound care, pain control, fluid and electrolyte management, and monitoring of superinfections. Nephrotoxicity, one of the most common adverse effect of gentamicin use, is associated with the therapy duration and not with serum concentrations. Generally, the glomerular filtration rate decrement is small and transient, and rarely patients progress to oliguric-anuric renal failure. Likewise, ototoxicity is more common in long-term gentamicin therapy. Furthermore, cochlear and vestibular damage sometimes are irreversible and can be accumulated after repetitive gentamicin exposes; aspirin use may attenuate this ototoxicity risk.
Gentamicin is a widely used antibiotic, being part of the medical practice since the 1940s. Although there is an increasing antimicrobial resistance rate, gentamicin is still a powerful option for many gram-negative infections, including severe ones. Physicians must always try to identify if the pathogen responsible for the infection is susceptible to gentamicin, allowing a more accurate use of it. Current evidence indicates that a high-dose, extended interval dosing approach is at least equally efficacious as traditional multiple doses, but less nephrotoxic and ototoxic, and, therefore, should be used whenever it is possible. Doses must be calculated based on patient weight and adjusted according to the GFR. Nursing should remember that the infusion time must not be less than 30 minutes and keep vigilant for hypersensitivity reactions. The pharmacists are essential for checking the prescribing dose and the necessary items for administration, as also for reviewing possible medication interactions. The healthcare team should be prepared to recognize and manage acute kidney injury and inner ear lesions, both potential adverse effects of gentamicin use.
|||Phillips I,Eykyn S,King BA,Jenkins C,Warren CA,Shannon KP, The in vitro antibacterial activity of nine aminoglycosides and spectinomycin on clinical isolates of common Gram-negative bacteria. The Journal of antimicrobial chemotherapy. 1977 Sep; [PubMed PMID: 143468]|
|||Hathorn E,Dhasmana D,Duley L,Ross JD, The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review. Systematic reviews. 2014 Sep 19; [PubMed PMID: 25239090]|
|||Finland M,Garner C,Wilcox C,Sabath LD, Susceptibility of pneumococci and Haemophilus influenzae to antibacterial agents. Antimicrobial agents and chemotherapy. 1976 Feb; [PubMed PMID: 5052]|
|||Kadry AA,Fouda SI,Elkhizzi NA,Shibl AM, Correlation between susceptibility and BRO type enzyme of Moraxella catarrhalis strains. International journal of antimicrobial agents. 2003 Nov; [PubMed PMID: 14602374]|
|||Beganovic M,Luther MK,Rice LB,Arias CA,Rybak MJ,LaPlante KL, A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Jul 2; [PubMed PMID: 29390132]|
|||Kohanski MA,Dwyer DJ,Hayete B,Lawrence CA,Collins JJ, A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 2007 Sep 7; [PubMed PMID: 17803904]|
|||Bratzler DW,Dellinger EP,Olsen KM,Perl TM,Auwaerter PG,Bolon MK,Fish DN,Napolitano LM,Sawyer RG,Slain D,Steinberg JP,Weinstein RA, Clinical practice guidelines for antimicrobial prophylaxis in surgery. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013 Feb 1; [PubMed PMID: 23327981]|
|||Wood MJ,Farrell W, Comparison of urinary excretion of tobramycin and gentamicin in adults. The Journal of infectious diseases. 1976 Aug; [PubMed PMID: 972272]|
|||Records RE, Gentamicin in ophthalmology. Survey of ophthalmology. 1976 Jul-Aug; [PubMed PMID: 785654]|
|||Vogelman B,Craig WA, Kinetics of antimicrobial activity. The Journal of pediatrics. 1986 May; [PubMed PMID: 3701535]|
|||Fausti SA,Henry JA,Schaffer HI,Olson DJ,Frey RH,McDonald WJ, High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. The Journal of infectious diseases. 1992 Jun; [PubMed PMID: 1583319]|
|||Kahlmeter G,Dahlager JI, Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. The Journal of antimicrobial chemotherapy. 1984 Jan; [PubMed PMID: 6365884]|
|||Nicolau DP,Freeman CD,Belliveau PP,Nightingale CH,Ross JW,Quintiliani R, Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrobial agents and chemotherapy. 1995 Mar; [PubMed PMID: 7793867]|
|||Connolly M,McAdoo J,Bourke JF, Gentamicin-induced anaphylaxis. Irish journal of medical science. 2007 Dec; [PubMed PMID: 17724569]|
|||Chen Y,Huang WG,Zha DJ,Qiu JH,Wang JL,Sha SH,Schacht J, Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hearing research. 2007 Apr; [PubMed PMID: 16844331]|